Form 4 for IMVT Immunovant, Inc.
Accepted 2025-04-03 00:00:00 ET · period of report 2025-04-01 · accession 0001764013-25-000043 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-04-03 | 2025-04-01 | IMVT | Fromkin Andrew J. | Dir | A - Grant | $0.00 | +16.2K | 108.1K | +18% | $0 |
| D | 2025-04-03 | 2025-04-01 | IMVT | Fromkin Andrew J. | Dir | A - Grant | $0.00 | +7,600 | 7,600 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-04-01 | A | A | 16,188 | $0.00 | 108,101 | D | — | — | (F1) These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A. |
| 2 | Derivative | Stock Option (right to buy) | 2025-04-01 | A | A | 7,600 | $0.00 | 7,600 | D | $15.20 · — to 2035-04-01 | 7,600 Common Stock | (F2) The shares underlying the options will vest on April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date. |